Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04175977 · ClinicalTrials.gov registry record · NA

The Hospice Advanced Dementia Symptom Management and Quality of Life Trial (HAS-QOL)

A NA study, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
44,143
Enrollment target

NCT04175977 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 44,143 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04175977, a NA study, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
44,143 participants
Enrollment target

Study Summary

The Aliviado Dementia Care Program (formerly known as the Dementia Symptom Management at Home Program, or DSM-H) was developed to implement dementia friendly care for persons with Dementia and their caregivers living in the community. Aliviado Dementia Care-Hospice Edition is a systems level quality assurance performance improvement program that includes interdisciplinary team training, validated assessment instruments, patient-centered care plans, treatment algorithms for behavioral and psychological symptoms of dementia and terminal delirium, and caregiver education pamphlets. Utilizing the R61/R33 mechanism, the Aliviado Dementia Care-Hospice Edition was successfully implemented in 2 sequential pilot trials in the hospice setting in 2019 (R61 phase). Following the successful pilot trials and the attainment of the R61 milestones, the investigators now seek to test the effectiveness of Aliviado Dementia Care-Hospice Edition in a pragmatic RCT in 25 hospice agencies across the nation (R33 phase) on its ability to reduce antipsychotic use (primary outcome) and effect quality (secondary and exploratory outcomes).

Interventions

  • BEHAVIORAL Usual Care
  • BEHAVIORAL Aliviado Dementia Care-Hospice Edition QAPI program

Trial Details

FieldValue
Enrollment Target 44,143 participants
Start Date 2020-01-01
Est. Completion 2024-08-13
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT04175977

The ClinicalTrials.gov registry entry for NCT04175977 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44,143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.

NCT04175977 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04175977 about?

NCT04175977 is a clinical study titled "The Hospice Advanced Dementia Symptom Management and Quality of Life Trial (HAS-QOL)". The Aliviado Dementia Care Program (formerly known as the Dementia Symptom Management at Home Program, or DSM-H) was developed to implement dementia friendly care for persons with Dementia and their caregivers living in the community. Aliviado Dementia Care-Hospice Edition is a systems level quality...

What is the current status of trial NCT04175977?

This trial is currently completed. It is a NA study. The enrollment target is 44,143 participants. The study started on 2020-01-01. Estimated completion is 2024-08-13.

What interventions are being tested in trial NCT04175977?

The interventions under investigation include: Usual Care (BEHAVIORAL), Aliviado Dementia Care-Hospice Edition QAPI program (BEHAVIORAL).

Who is sponsoring clinical trial NCT04175977?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.